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Abstract
Background:  Crimean-Congo Hemorrhagic Fever virus (CCHFV), a member of the genus
Nairovirus, family Bunyaviridae, is a tick-borne pathogen causing severe disease in humans. To better
understand the CCHFV life cycle and explore potential intervention strategies, we studied the
biosynthesis and intracellular targeting of the glycoproteins, which are encoded by the M genome
segment.
Results: Following determination of the complete genome sequence of the CCHFV reference
strain IbAr10200, we generated expression plasmids for the individual expression of the
glycoproteins GN  and GC, using CMV- and chicken β -actin-driven promoters. The cellular
localization of recombinantly expressed CCHFV glycoproteins was compared to authentic
glycoproteins expressed during virus infection using indirect immunofluorescence assays,
subcellular fractionation/western blot assays and confocal microscopy. To further elucidate
potential intracellular targeting/retention signals of the two glycoproteins, GFP-fusion proteins
containing different parts of the CCHFV glycoprotein were analyzed for their intracellular
targeting. The N-terminal glycoprotein GN localized to the Golgi complex, a process mediated by
retention/targeting signal(s) in the cytoplasmic domain and ectodomain of this protein. In contrast,
the C-terminal glycoprotein GC remained in the endoplasmic reticulum but could be rescued into
the Golgi complex by co-expression of GN.
Conclusion:  The data are consistent with the intracellular targeting of most bunyavirus
glycoproteins and support the general model for assembly and budding of bunyavirus particles in
the Golgi compartment.
Background
Crimean-Congo hemorrhagic fever virus (CCHFV) is a
member of the genus Nairovirus, one of five genera in the
family Bunyaviridae [1]. Bunyaviruses are enveloped parti-
cles with a tripartite, single stranded RNA genome of neg-
ative polarity [2-4]. The three genome segments encode
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four structural proteins: the RNA-dependent RNA
polymerase (L protein) is encoded by the large (L) seg-
ment, the glycoproteins (GN and GC; previously referred
to as G1 and G2) are encoded by the medium (M) seg-
ment, and the nucleocapsid protein (N) is encoded by the
small (S) segment [2-4].
The virus glycoproteins are likely to play an important
role in the natural tick-vertebrate cycle of the virus as well
as for the high pathogenicity in humans. Indeed, a highly
variable mucin-like region at the amino terminus of the
CCHFV glycoprotein precursor has recently been identi-
fied, a unique feature of nairoviruses within the family
Bunyaviridae [5]. A similar serine-threonine-rich domain
has been associated with increased vascular permeability
and development of hemorrhages in Ebola hemorrhagic
fever [6].
The Nairovirus genus includes 34 described viruses and is
divided into seven different serogroups [1]. Only three
viruses are known to cause disease: CCHFV, Dugbe virus,
and Nairobi sheep disease virus. CCHFV is an arthropod-
borne pathogen and the causative agent of a serious form
of hemorrhagic fever [7-9] with mortality rates ranging
from 15 to 60% [10-17]. The virus is endemic in parts of
Africa, Southeastern Europe and Asia as far east as western
China [16,18,19]. The geographic distribution of CCHFV
infections corresponds most closely with the distribution
of Hyalomma ticks, suggesting their principal vector role
[18,20,21]. Hyalomma ticks normally feed on a variety of
livestock (sheep, goats, cattle, and ostriches), large wild
herbivores, hares, and hedgehogs, which can become
infected with CCHFV [13,18,22,23]. In contrast to human
infections, infection in these animals generally results in
inapparent or subclinical disease but generates viremia
levels capable of supporting virus transmission to unin-
fected ticks [10,18,21,23-25]. Transmission to humans
occurs either by bites from infected ticks or direct contact
with blood or tissues of infected livestock. Nosocomial
infections are common [26] and represent a major prob-
lem in health care institutions [27].
The widespread geographical distribution of CCHFV, its
ability to produce severe human disease with high mortal-
ity rates, and fears about its intentional use as a bioterror-
ism agent http://www.bt.cdc.gov/Agent/Agentlist.asp
makes CCHFV an extremely important human pathogen
and a worldwide public health concern. Case manage-
ment and intervention strategies would greatly benefit
from knowledge of the biology and pathogenesis of the
virus.
Recently, the expression strategy and biosynthesis of the
CCHFV glycoproteins have been studied in more detail
including the identification of precursor cleavage sites and
the determination of the exact N termini of the two major
cleavage products, GN and GC [5,28]. SKI-1, also respon-
sible for the proteolytic processing of the Lassa virus glyc-
oprotein precursor [29], has been identified as the cellular
protease responsible for the processing step that generates
the N-terminus of mature GN. Another yet unidentified
protease is required for GC processing. However, the exact
C-terminus of GN could not yet been determined. Two
cleavage sites have been predicted for this processing step,
one at amino acid position 808 (RKLL) and the other at
940/944 (KKRKK) favouring the cellular proteases SKI-1
and furin, respectively, as the responsible proteases [28].
Bunyaviruses are known to bud from Golgi membranes
and the budding site seems to be defined by an retention
of the glycoproteins GN and GC at that particular site
[3,4]. From a number of studies which have addressed the
mechanisms of Golgi targeting and retention, one can
conclude that the N-terminal located glycoprotein
appears to carry the appropriate signal(s) [30-40] So far,
no studies have investigated Golgi targeting and retention
of nairovirus glycoproteins.
In this study we cloned the complete M segment ORF of
CCHFV, strain IbAr10200, into different expression plas-
mids. Expression and intracellular localization of the glyc-
oproteins GN and GC were studied and compared to
glycoproteins generated by virus infection. Using recom-
binant fusion proteins between the green fluorescence
protein (GFP) and CCHFV glycoproteins, the Golgi target-
ing/retention signal could be mapped to a hydrophobic
region within the cytoplasmic domain of the GN protein.
Results
Sequence determination of the full-length CCHFV M 
segment
The complete M segment nucleotide sequences of two dif-
ferent sources of CCHFV, strain IbAr10200, was deter-
mined and compared to previously published sequences
[GenBank: U39455]. Several nucleotide changes resulting
in amino acid changes in the glycoprotein precursor were
identified (Table 1). In two different CCHF viral RNA
samples eight amino acid changes and two silent nucle-
otide changes could be detected. Four additional amino
acid changes were found in sample #2 as well as four
silent nucleotide changes not leading to any amino acid
alteration. CCHFV RNA sample #1 showed two additional
unique amino acid changes.
Furthermore, we determined the sequences of the exact
ends of the M segment using an RNA ligation approach.
Beside constructs with nucleotide deletions due to RNA
degradation prior to RNA ligation several full-length
sequences were determined, demonstrating the expected
homologous RNA ends compare to the CCHF S and LVirology Journal 2005, 2:42 http://www.virologyj.com/content/2/1/42
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segments (Fig. 1). Especially the first and last nine nucle-
otides of the CCHF M vRNA segment showed high com-
plementarity to the L and S segment ends (bold and
italicized nucleotides in Fig. 1), confirming their role as
important cis-acting elements for RNA polymerase bind-
ing [41,42].
Expression of CCHFV glycoproteins
Based on the recently published N-terminal sequence
determination of mature CCHFV glycoproteins [5] and
using the above described determined CCHFV M segment
sequence (sample #1), expression plasmids for both glyc-
oproteins GN and GC as well as for the glycoprotein precur-
sor (GPC) were generated. Since the C-terminus of
CCHFV GN has not yet been determined ([28]; S. Nichol:
pers. communication) two constructs were generated con-
taining an N-terminal Influenza HA-tag for detection:
pCMV CCHF GN "short" (GNs) and pCMV CCHF GN
"long" (GNl). Glycoprotein expression was first analyzed
by immunoblot using CCHFV-specific polyclonal or HA-
tag antibodies. The CCHF full-length glycoprotein precur-
sor construct (pCAGGS CCHFV GPC) was successfully
expressed and correctly processed into the cleavage frag-
ments GC and GN (Fig. 2, lane 2). Molecular weights (GC,
37 kDa and GN, 75 kDa) as determined by immunoblot
analysis were in accordance with those of the GC and GN
Table 1: Sequence comparison of available CCHFV IbAr10200 M segment sequences
CCHF IbAr10200 Nucleotide changes compare to U39455 
(vRNA position*)
Amino acid changes compare to 
U39455*
Samples 1 and 2 83: C →  T1 6 7 1 :  G l y  →  Arg
713: T →  C1 4 6 1 :  S e r  →  Gly
1621: T →  C1 1 5 8 :  G l u  →  Gly
2263: G →  T9 4 4 :  T h r  →  Lys
2926: C →  T7 2 3 :  A r g  →  Lys
2964: A →  G 710: – (silent)
3512: C →  T 528: Val →  Ile
3550: A →  G5 1 5 :  P h e  →  Ser
4044: G →  T 350: – (silent)
4981: T →  G3 8 :  H i s  →  Pro
Sample 2 3425: T →  C 557: Asn →  Asp
3427: C→  A 556: Cys →  Phe
3429: G →  A 555: – (silent)
3435: T →  A 555: – (silent)
3441/42: GT →  AG 551: Asp →  Ala
3444: A →  T 550: – (silent)
4247: G →  A 282: – (silent)
4610: T →  G1 6 2 :  T h r  →  Pro
Sample 1 2760/61: TA →  AT 778: Ile →  Asn
4684: G →  A1 3 7 :  S e r  →  Phe
* based on [GenBank: U39455] position numbering
Schematic presentation of the predicted base-paired ends of the CCHFV M vRNA segment Figure 1
Schematic presentation of the predicted base-paired ends of the CCHFV M vRNA segment. The first nine nucle-
otides as well as nucleotides at position 11 at both RNA ends are highly conserved within the three genome segments (bold, 
italics), whereas the first thirteen nucleotides at the 3' and 5' vRNA ends are inverted complementary and can form base-
paired terminal regions.
CCHFV
M segment
TCTCAAAGAAATAGTG...
AGAGTTTCTTTATGAA...
||||||||||||| |
5`
3`
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expressed in CCHFV-infected VeroE6 cells (Fig. 2, lane 1).
CMV-driven HA-GNs and HA-GNl expression resulted in a
protein of approximately 75 kDa (Fig. 2, lanes 3 and 4),
similar to authentic GN  glycoprotein seen in CCHFV-
infected cells (Fig. 2, lane 1). Expression of chicken β -
actin-driven GC resulted in a product of approximately 37
kDa, again similar to GC expression in CCHV-infected
cells (Fig. 2, lane 5). The data demonstrates that each glyc-
oprotein can be authentically expressed individually from
separate plasmids (e.g., pCMV GNs, pCMV GNl and
pCAGGS GC) as well as from a clone encoding the GPC
precursor (pCAGGS GPC) using polyclonal CCHFV-spe-
cific and HA-tag antibodies (Fig. 2). Expression could also
be confirmed using CCHFV-specific GC and GN antipep-
tide antibodies which were kindly provided by S. Nichol,
CDC) (data not shown).
Intracellular localization of CCHFV glycoproteins
Indirect immunofluorescence assays (IFA) were initially
performed to analyze the cellular localization of CCHFV
glycoproteins. For this, different CCHFV glycoprotein
expression plasmids were individually transfected into
BHK-21 or 293T cells and 24 to 48 h post transfection the
cells were fixed with acetone/methanol or paraformalde-
hyde for intracellular (Fig. 3A) or surface immunofluores-
cence analysis (Fig. 3B), respectively. HA-specific
monoclonal antibodies were used to detect the two forms
of individually expressed N-terminal HA-tagged GN (Fig.
3A: b, c, g, h) and CCHFV G C-specific antibodies were
used to monitor β -actin promoter-driven GC expression
products (Fig. 3A: a, f). In addition, a CCHFV-specific
antiserum was used to detect GN and GC expression from
full-length glycoprotein precursor construct pCAGGS
GPC (Fig. 3A: d, i) as well as in CCHFV-infected cells (Fig.
3A: e, j). In all cases GN and GC were detected intracellular
but never on the cell surface (Figs. 3A and 3B). Mock-
infected and -transfected cells were used as negative con-
trols (data not shown). Two different cell lines were used
to exclude artificial cell type-specific localization pattern
of CCHFV glycoproteins.
In a next step we tried to specify the intracellular localiza-
tion of CCHFV GN and GC glycoproteins expressed from
plasmids encoding either the individual glycoproteins or
the precursor GPC. Intracellular staining pattern of
CCHV-infected cells as well as cells expressing the CCHFV
precursor GPC revealed a Golgi complex staining pattern
independent of the antibodies used for detection of the
individual glycoproteins (Fig. 3A: d, e, i, j). Subsequently,
we analyzed the intracellular localization of individually
expressed GN and GC. Whereas individually expressed
GN showed a Golgi complex localization (Fig. 3A: b, c, g,
h), individually expressed GC accumulated in the perinu-
clear region of the cell indicative of ER localization (Fig.
3A: a, f). Confirmation for these results were achieved by
co-immunofluorescence analyzed on a confocal micro-
scope using CCHFV glycoprotein-specific or HA-specific
antibodies and either antibodies directed against the ER-
specific marker molecule calreticulin or direct staining of
the Golgi region with BODIPY-TR C5 ceramides (Fig. 4).
Again, CCHFV GN expression from the two expression
plasmids pCMV GNs and pCMV GNl overlapped with
Golgi staining (Fig. 4: e, f), whereas GC expression over-
lapped with that of calreticulin (Fig. 4: d). However, co-
expression of both CCHFV glycoproteins either from the
glycoprotein precursor plasmid or from simultaneous
transfection of the two expression plasmids resulted in
Golgi targeting of both glycoproteins (Fig. 4: c, g) strongly
indicating that GN drives the Golgi localization and that
GC needs to interact with GN in order to be transported
out of the ER.
To further strengthen the association of CCHFV glycopro-
teins with intracellular membrane-containing compart-
ments such as ER and Golgi complex, we performed
subcellular fractionation experiments. This method
allows the separation of soluble proteins from mem-
brane-associated proteins. CCHFV-infected cells were
used for comparison (Fig. 5: lane 1). As expected all
expressed CCHFV glycoproteins were exclusively found in
the pellet fractions, which contain membrane-associated
proteins. This confirms the intracellular localization of
these proteins with membrane structures and together
with the co-immunofluorescence data confirms either ER
Western blotting of CCHFV glycoproteins after transfection  of different expression plasmids Figure 2
Western blotting of CCHFV glycoproteins after 
transfection of different expression plasmids. BHK-21 
cells were either infected with CCHFV (lane 1) or trans-
fected with individual CCHFV glycoprotein expression plas-
mids (lanes 2–5). Twenty-four hours post infection/
transfection cells were harvested and cell lysate used for 
western blotting, using immune serum specific against 
CCHFV IbAr10200. Protein bands with expected sizes were 
detected and confirmed successful expression of CCHFV 
glycoproteins.
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Indirect immunofluorescence assays of CCHFV glycoproteins after transfection of different expression plasmids Figure 3
Indirect immunofluorescence assays of CCHFV glycoproteins after transfection of different expression plas-
mids. BHK-21 and 293T cells were transfected with CCHFV glycoprotein expression plasmids. Twenty-four hours post trans-
fection cells were fixed and stained with CCHFV-specific or anti-HA antibodies. A: Cells fixed with methanol/acetone allow 
analyses of intracellular proteins. Polyclonal antibodies against CCHFV GC were used for GC detection (a, f). CCHFV GN 
expression from two different CMV-driven expression plasmids was analyzed using anti-HA tag antibodies (b, c, g, h). GN and 
GC expressed from the GPC were studied using polyclonal anti-CCHFV antibodies (d, i) as well as specific antipeptide antibod-
ies against GN and GC (data not shown). CCHFV-infected cells served as controls (e, j). B: Cells fixed with paraformaldehyde 
were analyzed for CCHFV G expression on cellular surfaces. GC was stained using anti-CCHFV GC antibodies, GN with anti-
HA tag, and mature CCHFV proteins derived from the GPC with anti-CCHFV antibodies. No clearly visible staining correlates 
with no detectable surface expression.Virology Journal 2005, 2:42 http://www.virologyj.com/content/2/1/42
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or Golgi localization (Fig. 5: lanes 2 to 5). To evaluate the
described approach control experiments using either the
soluble CCHFV N proteins or the Golgi marker Mannosi-
dase II were performed. As expected CCHF N protein was
exclusively found in the soluble fraction, whereas the
Golgi marker protein was only detected in the membrane-
associate fraction.
Signals for intracellular targeting of CCHFV glycoproteins
After determining the intracellular localization of the
CCHFV glycoproteins, we next were interested to deter-
mine the signals for intracellular targeting. For this, we
generated GFP-fusion proteins containing different frag-
ments of the GC or GN proteins attached to GFP. On the
basis of published data obtained with other bunyaviruses
we expected Golgi localization signals rather within the
transmembrane or cytoplasmic domains than in the ecto-
domain [3,4]. A CMV-driven GFP expression plasmid
(pHL2823, Flick and Hobom, unpublished) was used as a
cloning vector for fusing different regions of the CCHFV
glycoproteins to the C-terminus of the GFP. Firstly, the
different PCR-amplified GN  cytoplasmic domain frag-
ments (Table 2) were cleaved with BsmBI and inserted
into pHL2823 after BamHI/XbaI endonuclease treatment.
In an alternative approach a signal peptide (Ig κ -chain sig-
nal of the pDisplay vector) was fused to the GFP N-termi-
nus to allow entry into the secretory pathway. Secondly,
the GN transmembrane domain (TM I) was inserted using
a hybridized oligonucleotide linker (RF372/RF373:
GATCCTTTGGCTATGT
AATAACCTGCATACTTTGCAAGGCCATTTTTTACTTGT-
TAATAATTGTTGGATAAT/
CTAGATTATCCAACAATTATTAACAAGTAAAAAATGGCC
TTGCAAAGTATGCAGGTTATTACATAGCCAAAG). The
expression of the resulting constructs GFP-GNA, GFP-GNB,
GFP-GNC, GFP-GND, GFP-GNE, GFP-GNF, GFP-GNG, GFP-
Intracellular co-localization studies of CCHFV glycoproteins and cellular compartment markers Figure 4
Intracellular co-localization studies of CCHFV glycoproteins and cellular compartment markers. BHK-21 cells 
were either infected with CCHFV or transfected with individual CCHFV glycoprotein expression plasmids. Twenty-four hours 
post infection/transfection cells were fixed with methanol/acetone and subsequently an indirect immunofluorescence assay was 
performed. DAPI-stained (for nucleus localization), Golgi or ER compartment stained and CCHFV G expression pictures were 
taken individually and subsequently merged to study the intracellular CCHFV G localization. a: CCHFV-infected cells stained 
for CCHF GN and GC proteins; b and c: CCHFV GPC expression plasmid-transfected cells stained for GN or GC, respectively; 
d: Cells transfected with CCHFV GC expression plasmid stained with GC-specific antibodies and co-stained with ER compart-
ment marker calreticulin; e: CCHFV GNs-transfected cells stained with HA tag-specific antibodies; f: CCHFV GNl-transfected 
cells stained with HA tag-specific antibodies; g: CCHFV GC expression pattern after co-transfection of CCHFV GNl and GC.
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GNH, and GFP-GNI (Fig. 6A) was first verified by immuno-
blot (data not shown). All constructs expressed GFP-
fusion proteins of expected sizes and were subsequently
used in co-localization studies. For this two different cell
lines (BHK-21 and 293T), for comparison purposes, were
transfected with the different plasmid DNAs and GFP flu-
orescence localization was analyzed using UV-micros-
copy.
The fusion protein GFP-GNI, containing the TM I of CCHF
GN was expressed in the cell cytoplasm in both used cell
lines (Figs. 6B and 6C: b) similarly to GFP expressed from
the basic vector pHL2823 (Figs. 6B and 6C: a). In case of
the signal peptide-containing GFP fusion protein a diffuse
staining consistent with the distribution throughout the
secretory system was observed (data not shown). Based on
this result we conclude that the transmembrane domain
TM I does not contain any intracellular targeting signal.
The fusion proteins GFP-GNA and GFP-GNB showed a
similar cytoplasmic expression pattern (Figs. 6B and 6C: c,
d). GFP-GNA contains the first 87 amino acids from the
cytoplasmic domain including the RKLL motif at position
808, which is a predicted protease cleavage motif for gen-
erating the C-terminus of the mature GN protein, whereas
GFP-GNB has 99 amino acids fused to the GFP C-termi-
nus, corresponding to the first GN cytosolic tail fragment,
which is followed by a second hydrophobic region pre-
dicted as a potential transmembrane domain 2 (TM II)
(compare Fig. 6A). Interestingly, the fusion proteins GFP-
GNC, GFP-GND, GFP-GNE, GFP-GNF, GFP-GNG, and GFP-
GNH, which contain longer fragments of the predicted GN
cytoplasmic domain including additional predicted
hydrophobic transmembran regions (Fig. 6A), showed an
increased level of similarity to the intracellular pattern of
GNl, which contained the entire GN cytoplasmic domain
up to the determined mature GC start (Figs. 6B and 6C: e-
j). The switch from a diffuse staining pattern to a Golgi
complex localization is caused by the addition of TM II to
the first 99 amino acids of the cytoplasmic domain
resulting in GFP-fusion proteins containing 122 amino
acids of the predicted GN cytoplasmic domain (Fig. 6A).
These results demonstrate that the Golgi targeting signal is
not located within the first 99 amino acids of the GN cyto-
plasmic domain. However, the addition of an additional
hydrophobic 23 amino acid stretch (TM II) result in a co-
localization of the GFP-fusion protein with the Golgi
complex marker mannosidase II (Fig. 7), demonstrating
that a Golgi localization signal is located within the pre-
dicted TM II.
The Golgi localization signal was further analyzed with
two more GFP-fusion proteins containing only the 23
amino acids from the predicted TM II directly fused to the
C-terminus of GFP. To determine if a specific primary
sequence within TM II was recognized as a signal or rather
the hydrophobic character of this region was crucial to tar-
get GFP to the Golgi complex, the 23 amino acids were
fused in two different orientations (Fig. 6A). BHK-21 (Fig.
6B) and 293T (Fig. 6C) cells were transfected with these
constructs and GFP expression and intracellular localiza-
tion were analyzed. Both GFP-fusion proteins showed
specific Golgi complex localization demonstrating that
TM II contains a Golgi localization signal and that the ori-
entation of the primary amino acid sequence is not
important for GFP translocation (Figs. 6B and 6C: k, l).
GFP fusion proteins containing either the predicted GC
TM (GFP GCA) or cytoplasmic domain (GFP GCB) showed
perinuclear staining, suggesting ER localization (Figs. 6B
and 6C: m, n).
Subsequent analyses of expressed GFP-GN fusion proteins
with subcellular fractionation approaches were performed
to confirm the association of the fusion proteins with
cellular membranes and to demonstrate the transition of
intracellular localization from a diffuse cytoplasmic to a
Golgi complex region pattern (Fig. 8). For this, mem-
brane-associated cellular proteins were separated from
soluble proteins and the different fractions analyzed via
immunoblot using GFP-specific antibodies. As expected,
constructs GFP GNI, GFP GNA, and GFP GNB, containing
only the TM I, 87 or 99 amino acids from the predicted GN
cytoplasmic domain, respectively, were only detected in
the soluble fraction (Fig. 8a; only shown for GNB),
Subcellular fractionation studies of expressed CCHFV  glycoproteins Figure 5
Subcellular fractionation studies of expressed 
CCHFV glycoproteins. CCHFV-infected or CCHFV G 
expression plasmid-transfected BHK-21 cells were used for a 
subcellular fractionation study to determine if CCHFV G 
proteins are membrane associated. The results shown are 
summarized from two independent experiments. M: mem-
brane fraction, S: soluble fraction, N: CCHF nucleoprotein, 
Man II: Mannosidase II. For quantification individual protein 
bands were analyzed and compared using the software 
Quantity One (BioRad).
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whereas GFP GNC and constructs with longer parts from
the GN cytoplasmic domain including the TM II region
were detected mainly in the pellet fraction containing
membrane-associated proteins (Fig. 8b). Constructs with
longer fragments of the GN cytoplasmic domain, includ-
ing additional TM regions, were exclusively detected
within the pellet fraction (e.g., GFP GNG; Fig. 8c). These
results confirmed our previous findings that the addition
of GN TM II results in a change of intracellular protein
localization and seems to mediate targeting to Golgi
membranes.
Discussion
Enveloped viruses, which do not acquire their lipoprotein
coat by budding through the plasma membrane bud at
internal membranes, including the inner nuclear mem-
brane (herpesviruses;[43], the ER (flaviviruses and
rotaviruses; [44,45], the intermediate compartment
(ERGIC) (coronaviruses and poxviruses; [46,47], and the
Golgi complex (rubellaviruses, coronaviruses, and bunya-
viruses; [4,46,48]. Usually, the accumulation of the viral
surface proteins in the specific intracellular compartment
determines the assembly and budding site of the virus.
This intracellular accumulation is dependent on certain
compartment-specific retention or retrieval signals.
For almost all bunyaviruses assembly and budding takes
place in the Golgi region [4,46,48]. However, so far no
common motifs could be identified for signals within
bunyaviral glycoproteins resulting in Golgi targeting and
accumulation. Indeed, even the locations of such signals
within bunyaviral glycoproteins are different. For the
phlebovirus Uukuniemi (UUK), a Golgi retention signal
could be identified within the membrane-proximal half
(aa1040) of the 81 aa long cytoplasmic domain of GN
[30,31,38]. In contrast, for the phlebovirus Punto Toro,
such signals were mapped to the transmembrane domain
(TM) and the adjacent amino acids of the GN cytoplasmic
domain [36,37]. A similar localization was recently
described for the Golgi retention signal in the GN of the
phlebovirus Rift Valley Fever (RVF) virus GN [34]. Nota-
ble, for the Old World hantavirus Hantaan (HTN) it was
reported that the conformation of the GN/GC complex
might play a more important role for Golgi accumulation
than an actual primary sequence motif [39].
While extensive studies have been performed regarding
intracellular budding sites and glycoprotein accumulation
for members of the genera Orthobunyavirus, Phlebovirus,
Hantavirus and Tospovirus [30,32,34-36,39,40], nothing is
known for members of the genus Nairovirus. Here we
demonstrated, for the first time, that the CCHFV GN pro-
tein is membrane associated and contains a Golgi locali-
zation motif. In addition we have mapped this signal to a
hydrophobic region (TM II) within the predicted cytoplas-
mic tail [5]. Co-expressed GN and GC result in a specific
Table 2: Features and construction details of different GFP-CCHFV G fusion proteins
Construct Oligo-nucleotide 
primer
Restriction 
endonuclease
PCR-fragment length Glycoprotein fragment 
[nt] Fragment length
GFP-G2I RF372
RF373
BamHI
XbaI
72 bp Oligonucleotide 
linker
3177-3113
64 nt
GFP-G2A RF364
RF363
BsmBI 296 bp 3114-2854
290 nt
GFP-G2B RF364
RF365
BsmBI 332 bp 3114-2818
296 nt
GFP-G2C RF364
RF366
BsmBI 401 bp 3114-2749
365 nt
GFP-G2D RF364
RF367
BsmBI 443 bp 3114-2707
407 nt
GFP-G2E RF364
RF368
BsmBI 512 bp 3114-2638
476 nt
GFP-G2F RF364
RF369
BsmBI 779 bp 3114-2371
743 nt
GFP-G2G RF364
RF370
BsmBI 848 bp 3114-2302
812 nt
GFP-G2H RF364
RF371
BsmBI 995 bp 3114-2155
959 nt
GFP-G1A RF361
RF362
BamHI
XbaI
210 bp 411-220
191 nt
GFP-G1B RF362
RF378
BglII
XbaI
288 bp 489-220
69 nt
* based on [GenBank: U39455] position numberingVirology Journal 2005, 2:42 http://www.virologyj.com/content/2/1/42
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Golgi accumulation and co-localization using specific
Golgi markers, whereas individual expressed GC is
retained in the ER. These results imply that the two
CCHFV glycoproteins have to interact and form hetero-
oligomers for a proper Golgi transport of GC.
GFP-fusion proteins containing different portions of the
CCHF GN glycoprotein allowed mapping of the Golgi tar-
geting sequence within the cytoplasmic domain. Interest-
ingly, we located the signal downstream of the predicted
protease cleavage site RKLL at position 808 of the CCHFV
precursor GPC, responsible for generating the C-terminus
of the mature GN protein [5,28], implying that this cleav-
age site might not be used during the maturation process
of GN. Furthermore, we could demonstrate that the addi-
tion of only the hydrophobic region from the predicted
TM II within the GN cytoplasmic domain targeted a GFP-
fusion protein to the Golgi complex. This shows that the
23 amino acids of TM II are sufficient and necessary for
targeting GFP to the Golgi region, whereas the first 99
amino acids from the cytoplasmic domain and the TM I
domain do not contribute to Golgi targeting.
The results obtained from the GFP-GN fusion proteins
seem contradictory to the studies with the GN expression
plasmid. IFA data combined with confocal microscopy co-
localization studies of cells transfected with GNs expres-
sion plasmids demonstrated a clear Golgi complex stain-
ing (Fig. 3A: b, g; Fig. 4e). Since GNs contains only the first
87 amino acids of the predicted cytoplasmic domain
without the predicted TM II sequence, we expected that
the corresponding GFP-fusion protein GFP-GNA would
show similar intracellular localization. However, the dif-
fuse staining throughout the cytoplasm of transfected cells
demonstrates that the first 87 amino acids are not suffi-
cient to target the GFP to the Golgi complex (GFP-GNA;
GFP-CCHFV G fusion proteins to identify Golgi and ER localization signals Figure 6
GFP-CCHFV G fusion proteins to identify Golgi and ER localization signals. BHK-21 and 293T cells were trans-
fected with individual GFP-CCHFV G fusion proteins. Twenty-four hours post transfection cells were analyzed via UV micros-
copy. A: Schematic presentation of different GFP-CCHFV G fusion proteins. Green labeled parts represent the GFP protein, 
red and blue labeled parts show the fragments of the CCHFV G cytoplasmic tails C-terminal fused to the GFP gene. White 
boxes symbolize the predicted hydrophobic transmembrane domains (TM). Numbers represent the amino acid position from 
the CCHFV GPC; B: BHK-21 cell analyses; C: 293T cell analyses.Virology Journal 2005, 2:42 http://www.virologyj.com/content/2/1/42
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Figs. 6B and 6C: c). A possible explanation for this dis-
crepancy is the existence of a second Golgi localization
signal located within the GN ectodomain. Such a signal
would be the reason for the Golgi localization pattern of
GNs, whereas GFP-GNC and fusion proteins containing
longer fragments of the predicted GN cytoplasmic domain
localize to the Golgi region because of a Golgi localization
signal located in TM II.
CCHFV GC protein expressed by its own retained in the ER
and did not relocate into the Golgi complex. Interestingly,
similar to all described GC  proteins of phleboviruses
CCHFV GC  proteins also contain a lysine-based ER
retrieval signal (KKXX; [49] within the predicted cytoplas-
mic domain. In case of single expressed GC protein this
signal is most likely responsible for the ER localization of
the protein, even though GFP-CCHF GCA fusion proteins
containing only the predicted TM showed perinuclear
staining pattern (Figs. 6B and 6C: m). However, co-expres-
sion with GN protein leads to interaction between these
two proteins most likely resulting in masking of the ER
retrieval signal and an accumulation of the heterodimer in
Intracellular co-localization analysis of GFP-CCHFV G fusion proteins Figure 7
Intracellular co-localization analysis of GFP-CCHFV G fusion proteins. 293T cells were transfected with a GFP-
CCHFV GN fusion protein construct encoding 123 amino acids from the GN cytoplasmic tail (GFP GNC). Twenty-four hours 
later cells were fixed with methanol/acetone. A subsequent indirect immunofluorescence using the Golgi compartment marker 
mannosidase II was performed and analyzed via UV microscopy. The merged picture clearly demonstrates the Golgi localiza-
tion of the fusion protein.
Subcellular fractionation studies of expressed GFP-CCHFV G fusion proteins Figure 8
Subcellular fractionation studies of expressed GFP-CCHFV G fusion proteins. Expression plasmids for GFP-CCHFV 
glycoprotein fusion protein were transfected into BHK-21 cells and used for a subcellular fractionation study to determine if 
fusion proteins containing different parts from the CCHFV GN cytoplasmic domain are soluble or membrane associated. A 
GFP-specific antibody was used for the immunoblot. Representative results from three constructs are shown. M: membrane 
fraction, S: soluble fraction.
Golgi merge GFP-GN C
35 kDa
30 kDa
MS
GFP-GNB GFP GNC
MS
GFP-GNG
MS
abcVirology Journal 2005, 2:42 http://www.virologyj.com/content/2/1/42
Page 11 of 14
(page number not for citation purposes)
the Golgi complex, due to the Golgi retention signal(s)
located on GN (Fig. 3A: d, e, i, j; Fig. 4g). A similar phe-
nomenon with conflicting transport/targeting signals was
previously described for the rubellavirus E1 and E2 pro-
teins [48,50,51].
Conclusion
In conclusion, we were able to express CCHF GN and GC
glycoproteins individually as well as from the precursor
GPC. GN could be localized to the Golgi compartment,
whereas GC was found in the ER. Co-expression of both
proteins resulted in Golgi rescue of GC, indicating that
proper interaction between GN and GC is important for
transportation of the heterodimer out of the ER. The
potential Golgi targeting signal could be localized to a
hydrophobic region within the cytoplasmic domain in the
GN  protein. Furthermore, our results suggest that
additional signals could be localized within the GN ecto-
domain.
Further characterization of the CCHFV GN Golgi retention
signals could provide helpful information to understand
the proteolytic cleavage event(s) of the GPC and the glyc-
oprotein maturation process. The different CCHFV G
expression plasmids might show also useful for the
generation of virus-like particles (VLPs) as well as for iden-
tification of interaction sites between the viral glycopro-
teins and the ribonucleoproteins.
The identification of the potential budding site(s) of nai-
roviruses and the detailed analysis of the Golgi localiza-
tion signal of the CCHFV GN  protein will allow
subsequent studies for targeting the glycoprotein accumu-
lation during the development of antiviral strategies or
even for rational vaccine design.
Methods
Cells and virus
BHK-21 (baby hamster kidney), 293T (human embryonic
kidney), VeroE6 (African green monkey kidney) and
SW13 cells (human adenocarcinoma cells)(American
Type Culture Collection) were grown on plastic dishes in
Glasgow (BHK-21), Eagle's minimal essential (293T,
VeroE6), or Leibovitz L15 (SW13) medium, respectively,
supplemented with 5 to 10% fetal calf serum, 2 mM L-
glutamine, 100 IU of penicillin/ml, and 100 µg of strepto-
mycin/ml (Invitrogen). The CCHFV, strain IbAr10200,
isolated in 1970 from ticks (Hyalomma excavatum) in
Nigeria (Sokoto), kindly provided by Special Pathogens
Branch, Centers for Disease Control and Prevention,
Atlanta (T. G. Ksiazek), was used for all experiments. The
CCHFV stocks were prepared on SW13 cells by infection
of T162 cell culture flasks with a 1:100 dilution. Superna-
tant was collected three days post infection (p.i.), clarified
from cell debris by low speed centrifugation (3,000 × g, 10
min, 4°C), and aliquots were stored in liquid nitrogen.
Virus titers were determined either by plaque assay or 50%
tissue culture infectious dose assay (TCID50).
Sequence determination of the full-length CCHFV M 
segment
Total RNA was isolated 7 days post infection from VeroE6
cells infected with CCHFV (1:1000 dilution of virus stock;
10-3 pfu, RNA sample #1). Additional CCHFV RNA was
kindly provided by J. Smith, USAMRIID, Alphavax, Dur-
ham, N.C. (RNA sample #2). CCHFV specific M segment
vRNA or cRNA molecules were reverse transcribed using
the primers CCHF M1
(TCTCAAAGAAATAGTGGCGGCACGCAGTC) or CCHF
M2 (TCTCAAAGAAATACTTGCGGCACGTCAGT) for the
reverse transcription reaction, respectively. The resulting
cDNA molecules were used as templates for subsequent
PCR reactions producing overlapping PCR fragments cov-
ering the entire CCHFV M segment. PCR products were
inserted into pCR4 using the TOPO TA cloning kit
(Invitrogen). Prior to sequence determination, positive
clones were screened by PCR technology (primer TOPO F:
AGCTCGGATCCACTAGTAACG and TOPO R:
ATGCTCGAGCGGCCGCCAGTG) and restriction enzyme
digest (EcoRI). For vRNA and cRNA-based constructs three
of the cloning plasmids were sequenced using primers
specific for the M segment ORF. The sequence results were
aligned to the genebank sequence U39455 using the Align
Plus 5 program of the Clone Manager Professional Suite 6
(Scientific & Educational Software). Determined nucle-
otide exchanges and the corresponding amino acid differ-
ences are listed in Table 1. For sequence determination of
the M segment ends CCHFV specific vRNA and cRNA mol-
ecules were ligated using T4 RNA ligase (Roche) prior to
the reverse transcription reaction (vRNA: M32: AGAAC-
CAGAGGCCTGTTCAA, cRNA: M33:
AAGGTGTCTGTGCCGGTTGT). Subsequent PCR amplifi-
cation with primers CCHF M34 (AATACTAGTCTAAT
CCACTGGCTGGTGTT) and M35 (AATGAATTCT-
GCCGAACTGTTCTCTAC) generated fragments contain-
ing both segment ends. PCR products were inserted into
pCR4 (Invitrogen) for direct sequence determination as
described above. In total, 12 cRNA/mRNA and 37 vRNA
clones were analyzed using T7 and T3 promoter-specific
primers.
CCHFV glycoprotein expression plasmids
Based on the recently published N-terminal sequence
determination of mature CCHFV glycoproteins [5],
expression plasmids for both glycoproteins were gener-
ated. In case of the CCHFV GN two constructs were gener-
ated since the C terminus of the mature GN is not yet
experimentally determined: pCMV CCHF GN  "short"
(GNs) contains the GN-ORF from pos. 519 to 807, preced-
ing the predicted C-terminal cleavage site RKLL at positionVirology Journal 2005, 2:42 http://www.virologyj.com/content/2/1/42
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808 (44). pCMV CCHF GN "long" (GNl) consists of pos.
519 to 1040 extending the GN-ORF to the experimentally
determined N-terminal end of GC. The PCR fragments
(GNs: RF346/352, GNl: RF353/352) were inserted after
BsmBI endonuclease treatment into pDisplay (Invitrogen)
previously digested with BglII/XmaI digest, resulting in
CMV-driven (human cytomegalovirus immediate early
promoter and enhancer) expression plasmids for CCHFV
GN. The Ig κ -chain signal peptide sequence and the
hemagglutinin A (HA) epitope of the pDisplay vector
were used for correct intracellular processing and detec-
tion, respectively. The CCHFV GC  was PCR-amplified
using primers CCHF M9 (AGTTGGTCTAGCCAATGT-
GTG) and RF351 (AATCGTCTCAAATTCATGGAGAC
AGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTC
CAGGTTCCACTGGTGACTTCCTAGATAGTA-
CAGCTAAAGGCATG) (pos. 1041 to 1684).
BsmBI- and XhoI-restricted PCR fragments were inserted
into the plasmid pCAGGS/MCS [52] prior digested with
EcoRI/XhoI digest, resulting in a chicken β -actin-driven
expression plasmid for CCHFV GC. For correct
intracellular processing of the CCHFV GC we inserted the
Ig κ -chain signal peptide of the pDisplay vector via for-
ward oligonucleotide primer RF351.
Different expression strategies (CMV-, chicken β -actin-
driven) were used for the different CCHFV glycoproteins
to yield maximum expression levels.
Transfection
CCHFV glycoprotein expression plasmid DNA was trans-
fected into subconfluent BHK-21 or 293T cells (3 × 106)
using 2 to 4 µg of the respective plasmid and 8 µl of
liposome plus buffer (LipofectAMINE PLUS; Life Technol-
ogies, Invitrogen) mixed in serum-free MEM and incu-
bated for 15 min at room temperature. After addition of
12 µl of liposome reagent, incubation was continued for
a further 15 min. The cells were incubated at 37°C with
the DNA-Lipofectamine mixture for 3 h. To determine the
efficiency of transfection, plasmid pHL2823, expressing
enhanced GFP (EGFP) under the CMV immediate early
promoter and enhancer (R. Flick and G. Hobom,
unpublished), was transfected similarly. After further
incubation for 20–24 h in MEM containing 2% FCS, the
transfected cells were fixed and CCHFV glycoprotein
expression levels determined using indirect immunofluo-
rescence assays (IFA).
Indirect immunofluorescence assay
293T or BHK-21 cells grown on coverslips within a 6-well
dish were transfected as described above. After 20 to 44 h,
cycloheximide (final concentration of 0.18 mM) was
added when indicated to inhibit further protein synthesis.
The cells were incubated for an additional 2 to 5 h and
then washed with phosphate buffer saline (PBS, pH 7.5)
and fixed in methanol:acetone (50:50, V/V) for 20 min at
-20°C. Permeabilization was omitted by fixation with
paraformaldehyde when surface-expressed proteins were
to be detected. After fixation, cells were washed with PBS
and blocked for at least 30 min with PBS containing 5 %
bovine serum albumin (BSA). Poly- or monoclonal antis-
era were diluted in PBS containing 1 % BSA and incubated
for 1 h at room temperature. After several washes with
PBS, goat anti-rabbit or mouse immunoglobulin second-
ary antibodies conjugated to fluorescein isothiocyanate
(FITC) or tetramethyl rhodamin isothiocyanate (TRITC)
were incubated with the cells for 45 to 60 min at room
temperature. Procedures were repeated for double labe-
ling with a different antiserum and fluorescent probe, and
at the end of the procedure the slides were washed with
PBS overnight.
Intracellular localization of the glycoproteins GN  was
determined by co-localization with commercially availa-
ble organelle-specific fluorescent dyes (Molecular Probe
Inc., Oregon, USA): BODIPY-TR C5 ceramide was selected
as an indicator of the Golgi region. In addition Golgi
(mannosidase II; Sigma) and ER-specific (Calreticulin;
Sigma) monoclonal or polyclonal antibodies were used.
Confocal Microscopy
Sample preparation and immunocytochemical staining
were the same as for wide-field fluorescence microscopy.
The fluorescence staining patterns were analysed with a
ZEISS LSM 510 UV META laser scanning confocal micro-
scope (Jena, Germany) equipped with a Coherent Enter-
prise II 81 mW Argon UV laser, a Lasos 30 mW Argon
laser, and 5 mW HeNe laser. Images were acquired with a
C-apochromat 63/1.2 corr. water-immersion lens. FITC-
stained proteins were imaged with excitation at 488 nm
and with a 505 to 530 nm bandpass emission filter. Golgi
marker BODIPY-TR C5 ceramide were imaged with excita-
tion at 543 nm and with a 570 to 655 nm bandpass emis-
sion. DAPI-stained DNA was imaged with excitation at
364 nm and emission through a 385 to 470 bandpass fil-
ter. Merged pictures for analysis of intracellular co-locali-
zation were generated using Zeiss LSM Image Brower 3.2
software.
Membrane Fractionation
Alkaline carbonate extraction was performed on BHK-21
cells 24–48 h post transfection. The protocol described in
Current Protocols in Cell Biology Online, John Wiley &
Sons, Inc. was followed. Briefly, BHK-21 cells were trans-
fected with individual constructs as described before. At
24 to 48 h post transfection, supernatant was removed
and cells were washed three times with PBS followed by
an additional washing step with 100 ml NaCl. Occasion-
ally, the transfected cells would detach from the plateVirology Journal 2005, 2:42 http://www.virologyj.com/content/2/1/42
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thus, the non-adherent cells were isolated between washes
by microcentrifugation (2 min at 1000 × g). Remaining
cells were scraped (adherent) or resuspended (non-adher-
ent) into 1 ml of ice-cold 100 mM sodium carbonate, pH
11.5 and homogenized (five strokes) in a 2 ml Dounce
homogenizer. The homogenate was then incubated for 30
min on ice and 1 ml of sodium carbonate was added to
attain the necessary volume for subsequent ultracentrifu-
gation (2 ml). The homogenate was then centrifuged for
60 min at 50.000 rpm using a TLS-55 rotor (Beckman) at
4°C. Following centrifugation, the supernatant was trans-
ferred to a fresh tube and concentrated three to five times.
The pellet was resuspended in 250 µl of sodium carbon-
ate. Pellet and supernatant fractions were then mixed with
4× SDS-PAGE sample buffer containing β -mercaptoetha-
nol and run on SDS-PAGE. Protein gels were then trans-
ferred to PVDF transfer membrane (Amersham
Biosciences) using a Trans-blot SD semi-dry transfer
apparatus (Bio-Rad). Proteins were subsequently visual-
ized by immunoblot.
Western Blot
Following transfer, the blot was blocked overnight in 5 %
skim milk + 0.1 % Tween. The following morning, the
blot was washed three times with PBS/0.1 % Tween then
incubated with the primary antibody, e.g. anti-GFP
(Oncogene) at a 1:2000 dilution in PBS for 1 h at room
temperature with rocking. The blot was then washed three
times with PBS/0.1 % Tween and incubated with the sec-
ondary antibody, goat anti rabbit HRP (Sigma) at a
1:30.000 dilution in PBS for 1 h at room temperature with
rocking. The blot was then washed with PBS/0.1 %Tween
three times, followed by three washes with PBS. Proteins
were visualized using the ECL+plus Western Blotting
Detection system (Amersham Biosciences).
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